StockNews.AI
NVO
StockNews.AI
175 days

March 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO

1. Novo faces a securities fraud lawsuit. Investors may seek recovery. 2. Lawsuit covers November 2022 to December 2024. Alleged misstatements occurred. 3. REDEFINE 1 trial results fell short. Weight loss was only 22.7%, below target. 4. Stock dropped by $18.44 to close at $85.00. Investor sentiment was negatively impacted.

4m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit and below-target trial results have directly triggered a sharp stock decline. Historical cases involving clinical trial misses and legal actions have often led to sustained selloffs in healthcare stocks.

How important is it?

The lawsuit and disappointing trial data greatly affect investor sentiment and creditworthiness of NVO. Given the direct stock price drop and legal risk, the article is highly significant.

Why Short Term?

The immediate legal proceedings and adverse news have already impacted the share price. Similar prior events in the pharma sector typically result in near-term volatility.

Related Companies

LLY
NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=131752&wire=4 NVO investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their "REDEFINE 1" trial, "a 68-week efficacy and safety trial investigating subcutaneous CagriSema." The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release further indicated that participant patients were permitted to modify their own dosage during the trial and, as a result, only 57.3% of patients treated with CagriSema were on the highest dosage contemplated by the study.  Following this news, Novo's stock price fell by $18.44 per share to close at $85.00 per share. WHAT'S NEXT? If you suffered a loss in Novo during the relevant time frame, you have until March 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News